• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ispire Technology Inc.

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email
    SC 13G 1 ea0209320-13gliu_ispire.htm SCHEDULE 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    ISPIRE TECHNOLOGY INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    46501C100

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☐ Rule 13d-1(c)

     

      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP 46501C100

     

    1.

    Names of Reporting Persons

     

    Pride Worldwide Investment Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    British Virgin Islands

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.   

    Sole Voting Power

     

    33,250,000 (1)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    33,250,000 (1)

    8.

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    33,250,000 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    59.0%(1)(3)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

      

    2

     

     

    CUSIP 46501C100

     

    1.

    Names of Reporting Persons

     

    Tuanfang Liu

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ 

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    People’s Republic of China

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.   

    Sole Voting Power

     

    33,250,000 (1)

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    33,250,000 (1)

    8.

    Shared Dispositive Power

     

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    33,250,000 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☒

    11.

    Percent of Class Represented by Amount in Row (9)

     

    59.0%(1)(3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

      

    3

     

     

    CUSIP 46501C100

     

    1.

    Names of Reporting Persons

     

    Jiangyan Zhu

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☐        (b)  ☐ 

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    People’s Republic of China

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.   

    Sole Voting Power

     

    2,500,000(2)

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    2,500,000(2)

    8.

    Shared Dispositive Power

     

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,500,000(2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☒

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.4%(2)(3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

      

    (1) These shares are held directly by Pride Worldwide Investment Limited. Tuanfang Liu, the co-chief executive officer of the Issuer, is the sole shareholder of Pride Worldwide Investment Limited. Consequently, he may be deemed the beneficial owner of the shares held by Pride Worldwide Investment Limited. Mr. Liu disclaims beneficial interest in shares beneficially owned by his wife, Jiangyan Zhu, a director of the Issuer.
       
    (2) Jiangyan Zhu, a director of the Issuer and spouse of the Issuer’s co-chief executive officer, Tuanfang Liu, is the sole shareholder of Honor Epic International Limited, the direct owner of these shares. Consequently, she may be deemed the beneficial owner of the shares held by Honor Epic International Limited. Ms. Zhu disclaims beneficial interest in shares beneficially owned by her husband.
       
    (3) Based on 56,400,636 shares of common stock outstanding on May 10, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2024.

     

    4

     

     

    Item 1(a).Name of Issuer

     

    Ispire Technology Inc. (the “Issuer”)

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices

     

    19700 Magellan Drive

    Los Angeles, California

     

    Item 2(a). Names of Persons Filing

     

    Pride Worldwide Investment Limited, Tuanfang Liu, and Jiangyan Zhu (collectively, the “Reporting Persons”)

     

    Item 2(b). Address of Principal Business Office, or if None, Residence:

     

    19700 Magellan Drive

    Los Angeles, California

     

    Item 2(c). Citizenship

     

    Pride Worldwide Investment Limited is a company incorporated under the laws of British Virgin Islands. Tuanfang Liu and Jiangyan Zhu are citizens of People’s Republic of China.

     

    Item 2(d). Title of Class of Securities

     

    Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP Number

     

    46501C 100 

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      ☐ (a) Broker or Dealer registered under Section 15 of the Exchange Act.
         
      ☐ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
         
      ☐ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
      ☐ (d) Investment company registered under Section 8 of the Investment Company Act.
         
      ☐ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(E).
         
      ☐ (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(F).
         
      ☐ (g) A parent holding company or control person in accordance with Rule 13d 1(b)(1)(ii)(G).

     

      ☐ (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    5

     

     

      ☐ (i) A church plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
         
      ☐ (j) A non-U.S. institution in accordance with Rule 13d-1 (b)(1)(ii)(J)
         
      ☐ (k) Group, in accordance with Rule 13d-1 (b)(1)(ii)(K).
         
        Not applicable

     

    Item 4. Ownership

     

    The responses to Items 5-11 of the cover pages of this Schedule 13G including the footnotes are incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

     Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certifications

     

    Not Applicable

      

    6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE:  July 12, 2024

     

      Pride Worldwide Investment Limited
         
      By:   /s/ Tuanfang Liu
      Name:  Tuanfang Liu
      Title: Director

     

        /s/ Tuanfang Liu
      Name:  Tuanfang Liu
         
        /s/ Jiangyan Zhu
      Name:  Jiangyan Zhu

     

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

      

    7

     

    Get the next $ISPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    SEC Filings

    View All

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    6/26/25 4:30:08 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    5/23/25 4:30:34 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Burch Christopher Robert was granted 27,178 shares, increasing direct ownership by 188% to 41,658 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:30:47 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Key Leadership Appointments

    LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

    8/14/23 8:35:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

    Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

    5/12/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care